Literature DB >> 177195

Estrogen and prolactin receptor concentrations in rat mammary tumors and response to endocrine ablation.

E R DeSombre, G Kledzik, S Marshall, J Meites.   

Abstract

Estrogen and prolactin receptor concentrations were measured in 24 carcinogen-induced rat mammary tumors and correlated with the tumor response to host ovariectomy or hypophysectomy. It was found that essentially all of the tumors contained some specific estrogen receptor, and all but three contained prolactin receptor. The values for each receptor comprised a continuum from very low to relatively high concentrations, suggesting that previous considerations of hormone dependence on the basis of presence or absence of hormone receptors may be oversimplified. The concentration of each receptor tended to be lower in the hormone-independent than in the hormone-dependent tumors, but there were a number of hormone-independent tumors with higher receptor levels than some of the hormone-dependent tumors had. A better correlation of tumor response to endocrine ablation resulted from a combination of the 2 receptor levels than from either receptor concentration alone. These results suggest that there is a complex relationship between mammary tumor response to endocrine ablatin and levels of estrogen and prolactin receptors and that some tumors may be dependent upon 1 or both of these hormones for growth.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 177195

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Prolactin receptors: a comparison between chloramine-T and lactoperoxidase iodination.

Authors:  K Kuo-Jang; V D Ramirez
Journal:  J Endocrinol Invest       Date:  1978-07       Impact factor: 4.256

Review 2.  [Current status in the treatment of breast cancer. I. Endocrine management--change of concepts and outlook for the future (author's transl)].

Authors:  U Jehn; H Sauer; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-09-17

3.  Estrogen mitogenic action. I. Demonstration of estrogen-dependent MTW9/PL2 carcinogen-induced rat mammary tumor cell growth in serum-supplemented culture and technical implications.

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

4.  Micromethod for the determination of free and total prolactin receptors: measurement of receptor levels in normal and malignant mammary and prostate tissues.

Authors:  M Ben-David; T Kadar; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

Review 5.  Relation of the neuroendocrine system to the development and growth of experimental mammary tumors.

Authors:  J Meites
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

6.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

7.  Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.

Authors:  S De Placido; C Gallo; F Perrone; A Marinelli; C Pagliarulo; C Carlomagno; G Petrella; M D'Istria; G Delrio; A R Bianco
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

8.  Hormonal status and steroid metabolism in two transplantable rat mammary tumours.

Authors:  W R Miller; R Stewart; R A Hawkins
Journal:  Br J Cancer       Date:  1979-02       Impact factor: 7.640

9.  Morphology, growth characteristics and oestrogen-binding capacity of DMBA-induced mammary tumours from ovariectomized rats.

Authors:  E S Boylan; E H Fowler; J L Wittliff
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

10.  Effects of serial passage on the endocrine response and steroid metabolism of a rat mammary carcinoma.

Authors:  W R Miller
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.